SVF Endurance reports 10b5-1 sales of VIR shares at ~$6.05
Rhea-AI Filing Summary
SVF Endurance (Cayman) Ltd and related SoftBank entities reported insider sales of Vir Biotechnology, Inc. (VIR) common stock under a Rule 10b5-1 plan. The filings show a sale of 72,133 shares on 10/07/2025 at a weighted average price of $5.6029 and a sale of 466,242 shares on 10/08/2025 at a weighted average price of $6.0479. After the reported transactions, the beneficial ownership attributable indirectly to the reporting group declined from 16,087,611 shares to 15,621,369 shares. The filings state the sales were effected pursuant to a 10b5-1 trading plan entered on September 3, 2025, and identify SVF Endurance as a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P., with SB Investment Advisers (UK) Limited acting as AIFM.
Positive
- Sales executed under a documented Rule 10b5-1 plan, which provides pre-arranged compliance protection
- Filing discloses weighted-average prices and share ranges, and offers to provide breakdowns on request
Negative
- Beneficial ownership declined by 466,242 shares to 15,621,369 shares following the reported sales
- Large institutional holder reduced stake, which may be interpreted as downward pressure on insider ownership
Insights
Insider sales under a 10b5-1 plan reduced SoftBank's indirect stake by about 2.9.
The reported transactions show scheduled sales executed under a 10b5-1 plan, which is a pre‑arranged program that allows large holders to sell shares without contemporaneous trading intent. The group sold 72,133 shares at a weighted average of $5.6029 and 466,242 shares at a weighted average of $6.0479, leaving 15,621,369 shares indirectly owned.
Dependence on the 10b5-1 plan reduces the immediacy of signal from the sales, but the transactions do lower the block holding. Investors may watch outstanding share counts and block ownership disclosures over the next quarters for further scheduled sales or changes in beneficial ownership.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 466,242 | $6.0479 | $2.82M |
| Sale | Common Stock | 72,133 | $5.6029 | $404K |
Footnotes (1)
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.52 to $5.675. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.6101 to $6.325. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
FAQ
Were the VIR sales part of a trading plan?
How did the reported transactions change SoftBank's stake in VIR?
Which SoftBank entities filed the Form 4 for VIR?